This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Edward J. Fox, MD
Bristol-Myers US Pharmaceutical Group Evansville, Ind

JAMA. 1989;262(22):3127-3128.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply. —

We are pleased to respond to the questions about Questran raised by Dr Goldstein by assuring him that (1) the cholestyramine resin used in the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) was not contaminated, (2) currently marketed Questran is free of contamination, and (3) although a temporal association between cholestyramine resin and certain tumors has been observed, a causal relationship has not been established after more than 20 years of commercial availability and several hundred thousand patient-years of therapy dispensed.

The questions asked by Dr Goldstein appear to arise from the fact that, in April 1988, Bristol Laboratories initiated a recall because it determined that certain batches of bulk cholestyramine resin supplied by Rohm & Haas and used in the production of Questran contained very low levels of the agricultural chemicals dichlorodiphenyldichloroethylene and dichlorobenzophenone. These chemicals are related to the manufacture of a pesticide (dicofol) . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?